1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Auro Laboratories Limited

Auro Laboratories Limited

BBSE:AUROLAB
212.35
INR
-2.15
(-1.00%)
7.51EPS
33.58P/E
1.70BMarket Cap
Auro Laboratories Limited
BSE:AUROLAB
(Bombay Stock Exchange)

Recent

price

212.35

P/E

ratio

33.58

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
INR
34.82
42.37
69.94
53.49
51.74
44.42
55.12
64.33
73.11
68.84
84.93
80.93
83.85
84.56
30.68
49.32
57.97
Revenue per Share
0.33
0.42
1.23
0.93
1.29
1.41
1.31
5.66
7.06
6.51
11.52
4.56
3.92
12.5
2.95
5.67
7.51
Basic EPS, GAAP
-2.15
- -
2.34
7.19
-2.49
8.6
7.8
9.71
11.02
14.92
20.56
-10.57
5.26
30.18
8.05
-88.29
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
11.07
8.91
10.14
11.07
12.36
13.86
15.1
20.82
27.94
34.49
45.86
50.58
54.87
67.34
68.94
74.36
- -
Book Value per Share
11.07
8.91
10.14
11.07
12.36
13.86
15.1
20.82
27.94
34.49
45.86
50.58
54.87
67.34
68.94
74.36
- -
Tangible Book Value per Share
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
Basic Weighted Avg Shares
216
264
436
333
322
277
344
401
456
429
529
504
523
527
191
307
368
Sales/Revenue/Turnover
5.68
5.61
5.88
7.1
6.89
7.66
10.38
13.54
13.13
12.23
19.28
7.15
6.35
18.18
12.07
25.59
26.08
Operating Margin (%)
4
5
7
7
7
7
9
9
10
10
10
10
11
11
11
28
34
Depreciation Expense
2
3
8
6
8
9
8
35
44
41
72
28
24
78
18
35
48
Net Income, GAAP
- -
- -
- -
- -
- -
- -
72.11
25.34
27.51
28.13
31.66
26.57
29.13
24.68
2.24
26.52
21.1
Effective Tax Rate (%)
0.95
0.99
1.76
1.74
2.49
3.19
2.37
8.8
9.66
9.45
13.56
5.64
4.67
14.79
9.61
11.49
12.95
Profit Margin (%)
108
35
37
32
39
34
26
95
123
118
189
175
175
69
-8
22
- -
Working Capital
131
89
83
74
75
72
49
92
81
32
24
17
20
184
308
433
- -
LT Debt
69
56
63
69
77
86
94
130
174
215
286
315
342
420
430
463
- -
Total Equity
1.09
1.28
3.49
2.57
3.48
4.4
5.38
22.19
18.13
15.12
24.33
6.79
5.35
12.82
2.88
5.65
- -
Return on Invested Capital (%)
6.52
7.51
10.81
8.51
10.27
12.19
7.38
23.78
20.65
17.82
26.57
8.96
7.03
15.34
3.66
6.6
- -
Return on Capital (%)
2.97
4.2
12.91
8.76
11.01
10.79
9.03
31.53
28.95
20.84
28.67
9.47
7.43
20.46
4.33
7.91
- -
Return on Common Equity (%)

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
200
- -
LT Borrowings
- -
433
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
6
6
7
Market Capitalization
1,556
1,652
1,696

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
308
- -
Cash, Cash Equivalents & STI
- -
17
- -
Accounts Receivable, Net
- -
92
- -
Inventories
- -
135
- -
Total Current Liabilities
- -
286
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
200
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
18.92%
10.35%
7.86%
Free Cash Flow
-99.56%
-219.51%
-1,196.16%
Net Income, GAAP
57.96%
32.06%
92.14%
Sales/Revenue/Turnover
6.87%
-0.65%
60.74%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
57
31
31
74
191
2026
28
88
94
98
307
2027
88
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
1.21
0.57
0.08
0.63
2.95
2026
-0.17
1.15
3.13
1.56
5.67
2027
1.68
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Auro Laboratories Limited manufactures and sells active pharmaceutical ingredients, intermediates, and generic formulations primarily focused on anti-diabetic drugs such as Metformin Hydrochloride and Glibenclamide; other APIs including Chlorpheniramine Maleate, Chlorzoxazone, Frusemide, Ferrous Fumarate, Chloroquine Phosphate, Tramadol HCl, Aluminium Hydroxide Gel, Magnesium Hydroxide, Diclofenac Sodium, and Potassium Iodide; and intermediates like Glibenclamide Sulphonamide, Cis-Bromo Benzoate, 3,4,5-Trimethoxy Benzoic Acid, 2-Ethoxy Benzoic Acid, and 5-Bromo Phthalide. The company, founded in 1989 and headquartered in Mumbai, India, with a manufacturing facility in Tarapur, Maharashtra, operates under cGMP norms with certifications including ISO 9001:2000, WHO-cGMP, EU-GMP, and Certificate of Suitability from EDQM for products like Metformin Hydrochloride and Chlorphenamine Maleate, alongside US FDA DMF for Metformin Hydrochloride. It serves international markets including Egypt, Germany, Malaysia, Singapore, South Africa, Brazil, Spain, and the United Kingdom through exports, while also providing toll and custom manufacturing services for APIs and intermediates. In January 2024, Auro Laboratories entered into an agreement with Maharashtra Industrial Development Corporation to acquire leasehold land measuring 19,720 square meters in Tarapur for future expansion purposes; the company reported strong financial performance with standalone net sales reaching Rs 8.84 crore in September 2025, up 184.94% year-over-year.